Ownership and insider activity for Achieve Life Sciences, Inc. (ACHV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom.
Price
| Price | $7.42 |
| Market Cap | $762M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-19 | Stewart Richard Alistair | S-Sale | 20,626 | $175K |
| 2026-07-27 | Sellig Thomas | A-Award | 25,000 | $154K |
| 2026-07-27 | Sellig Thomas | A-Award | 16,700 | |
| 2026-07-27 | Martin Christopher Nathan | A-Award | 25,000 | $154K |
| 2026-07-27 | Martin Christopher Nathan | A-Award | 16,700 | |
| 2026-07-27 | Royston Aaron | A-Award | 25,000 | $154K |
| 2026-07-27 | Royston Aaron | A-Award | 16,700 | |
| 2026-07-27 | Waldman Reid Alexander | A-Award | 25,000 | $154K |
| 2026-07-27 | Waldman Reid Alexander | A-Award | 16,700 | |
| 2026-07-27 | Stewart Richard Alistair | A-Award | 25,000 | $154K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.2M | $5.3M | $9.5M | $16.7M | $35.9M | $43.0M | $24.7M | $15.5M | $12.7M | $20.9M |
| Short-term Investments | $10.2M | 0 | $5.1M | 0 | 0 | 0 | 0 | 0 | $21.6M | $15.5M |
| Receivables | $510000 | $9000 | $7000 | $8000 | 0 | $153000 | $105000 | $111000 | 0 | 0 |
| Inventory | 0 | $222000 | -$50000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.2M | $5.9M | $15.5M | $17.3M | $37.0M | $44.6M | $27.3M | $17.0M | $36.5M | $39.9M |
| Property, Plant & Equipment | $271000 | $59000 | $35000 | $386000 | $146000 | $64000 | $123000 | $79000 | $119000 | $64000 |
| Goodwill | $1034 | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Intangible Assets | $2755 | $2.5M | $2.3M | $2.1M | $1.9M | $1.6M | $1.4M | $1.2M | $974000 | $751000 |
| Total Assets | $27.5M | $9.9M | $19.1M | $21.1M | $40.3M | $47.5M | $30.0M | $19.4M | $38.6M | $41.8M |
| Accounts Payable | $2.1M | $213000 | $144000 | $859000 | $332000 | $841000 | $1.7M | $618000 | $1.9M | $867000 |
| Short-term Debt | $829000 | 0 | 0 | 0 | 0 | 0 | $16.1M | $16.7M | 0 | $3.7M |
| Total Current Liabilities | $8.5M | $2.0M | $3.3M | $2.9M | $2.9M | $4.5M | $21.6M | $20.8M | $6.7M | $9.1M |
| Long-term Debt | 0 | 0 | $12000 | 0 | 0 | $14.9M | 0 | 0 | $9.8M | $11.2M |
| Total Liabilities | $8.5M | $2.0M | $3.3M | $3.0M | $3.0M | $19.5M | $21.7M | $20.8M | $17.7M | $20.3M |
| Retained Earnings | -$196.9M | -$12.7M | -$25.4M | -$45.7M | -$60.4M | -$93.6M | -$135.9M | -$165.8M | -$205.6M | -$260.2M |
| Total Equity | $19.0M | $7.9M | $15.8M | $18.1M | $37.3M | $28.0M | $8.3M | -$1.4M | $20.9M | $21.5M |
| Total Debt | $106000 | $27000 | $35000 | $362000 | $169000 | $15.0M | $16.2M | $16.7M | $10.0M | $15.0M |
| Net Debt | -$25.6M | -$5.3M | -$14.6M | -$16.3M | -$35.7M | -$28.0M | -$8.5M | $1.2M | -$24.4M | -$21.4M |
| Working Capital | $18.7M | $3.9M | $12.3M | $14.5M | $34.0M | $40.0M | $5.7M | -$3.8M | $29.8M | $30.8M |
Financial Health
| Debt / Equity | -1.02 |
| Current Ratio | 0.95 |
Profitability
| Return on Equity | -892.07% |
| Return on Invested Capital | -21425.74% |
| Return on Assets | -59.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLO · ARCT · AVIR · CAPR · HUMA · IMRX · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ACHV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks